Glaukos Corporation $GKOS Shares Purchased by LPL Financial LLC

Key Points

• LPL Financial LLC raised its stake in Glaukos Corporation by 25.1% during the 1st quarter, owning 15,775 shares valued at approximately $1.55 million as reported in SEC filings.
• Recent analysis shows that Glaukos has received mixed ratings from analysts, with target prices ranging from $72.00 to $176.00 and an average rating of 'Moderate Buy'.
• Glaukos Corporation reported $124.12 million in revenue for the last quarter, outperforming analyst expectations, and indicated an optimistic forecast despite a negative EPS of ($0.24).

LPL Financial LLC lifted its stake in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 25.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,775 shares of the medical instruments supplier's stock after buying an additional 3,163 shares during the quarter. LPL Financial LLC's holdings in Glaukos were worth $1,553,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Bessemer Group Inc. lifted its stake in Glaukos by 133.9% during the first quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock worth $27,000 after purchasing an additional 158 shares during the last quarter. OneAscent Financial Services LLC bought a new position in Glaukos during the first quarter worth $408,000. Harbor Capital Advisors Inc. lifted its stake in Glaukos by 59.5% during the first quarter. Harbor Capital Advisors Inc. now owns 39,132 shares of the medical instruments supplier's stock worth $3,851,000 after purchasing an additional 14,593 shares during the last quarter. SG Americas Securities LLC lifted its stake in Glaukos by 35.2% during the first quarter. SG Americas Securities LLC now owns 4,924 shares of the medical instruments supplier's stock worth $485,000 after purchasing an additional 1,283 shares during the last quarter. Finally, Comerica Bank lifted its stake in Glaukos by 664.5% during the fourth quarter. Comerica Bank now owns 151,538 shares of the medical instruments supplier's stock worth $22,722,000 after purchasing an additional 131,715 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors.

Glaukos Stock Performance

Shares of NYSE GKOS traded up $1.59 during midday trading on Wednesday, reaching $95.38. 421,922 shares of the company traded hands, compared to its average volume of 1,161,423. Glaukos Corporation has a 52 week low of $77.10 and a 52 week high of $163.71. The stock has a 50-day moving average price of $95.83 and a 200 day moving average price of $100.19. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69. The company has a market cap of $5.47 billion, a price-to-earnings ratio of -57.80 and a beta of 0.78.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The business had revenue of $124.12 million for the quarter, compared to analysts' expectations of $115.49 million. During the same period in the previous year, the business earned ($0.52) earnings per share. The company's revenue was up 29.7% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on GKOS shares. Morgan Stanley reduced their price objective on Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. UBS Group raised their price objective on Glaukos from $125.00 to $134.00 and gave the stock a "buy" rating in a research note on Thursday, July 31st. Mizuho set a $130.00 price objective on Glaukos in a research note on Thursday, July 31st. Needham & Company LLC cut their target price on Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. Finally, BTIG Research reiterated a "buy" rating on shares of Glaukos in a research note on Monday, July 14th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Glaukos currently has a consensus rating of "Moderate Buy" and a consensus target price of $127.42.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.